

## RESEARCH ARTICLE

# Preferences of people living with HIV for differentiated care models in Kenya: A discrete choice experiment

Sagar Dommaraju<sup>1\*</sup>, Jill Hagey<sup>2</sup>, Thomas A. Odeny<sup>3,4</sup>, Sharon Okaka<sup>4</sup>, Julie Kadima<sup>4</sup>, Elizabeth A. Bukusi<sup>4</sup>, Craig R. Cohen<sup>1,5</sup>, Zachary Kwena<sup>4</sup>, Ingrid Eshun-Wilson<sup>5</sup>, Elvin Geng<sup>5</sup>

**1** Department of Global Health, University of California San Francisco, San Francisco, California, United States of America, **2** Department of Obstetrics and Gynecology, Duke University Hospital, Durham, North Carolina, United States of America, **3** Department of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, United States of America, **4** Kenya Medical Research Institute, Nairobi, Kenya, **5** Department of Medicine, University of California San Francisco, San Francisco, California, United States of America

\* [Sagar.Dommaraju@northwestern.edu](mailto:Sagar.Dommaraju@northwestern.edu)



## OPEN ACCESS

**Citation:** Dommaraju S, Hagey J, Odeny TA, Okaka S, Kadima J, Bukusi EA, et al. (2021) Preferences of people living with HIV for differentiated care models in Kenya: A discrete choice experiment. PLoS ONE 16(8): e0255650. <https://doi.org/10.1371/journal.pone.0255650>

**Editor:** D. M. Basavarajaiah, Karnataka Veterinary Animal and Fisheries Sciences University, INDIA

**Received:** August 7, 2020

**Accepted:** July 21, 2021

**Published:** August 25, 2021

**Peer Review History:** PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0255650>

**Copyright:** © 2021 Dommaraju et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its [Supporting Information](#) files. We have included the raw data as a .db3 file, which can be accessed by software that uses the

## Abstract

### Introduction

To improve retention on HIV treatment in Africa, public health programs are promoting a family of innovations to service delivery—referred to as “differentiated service delivery” (DSD) models—which seek to better meet the needs of both systems and patients by reducing unnecessary encounters, expanding access, and incorporating peers and patients in patient care. Data on the relative desirability of different models to target populations, which is currently sparse, can help guide prioritization of specific models during scale-up.

### Methods

We conducted a discrete choice experiment to assess patient preferences for various characteristics of treatment services. Clinically stable people living with HIV were recruited from an HIV clinic in Kisumu, Kenya. We selected seven attributes of DSD models drawn from literature review and previous qualitative work. We created a balanced and orthogonal design to identify main term effects. A total of ten choice tasks were solicited per respondent. We calculated relative utility (RU) for each attribute level, a numerical representation of the strength of patient preference. Data were analyzed using a Hierarchical Bayesian model via Sawtooth Software.

### Results

One hundred and four respondents (37.5% men, 41.1 years mean age) preferred receiving care at a health facility, compared with home-delivery or a community meeting point (RU = 69.3, -16.2, and -53.1, respectively;  $p \ll 0.05$ ); receiving those services from clinicians and pharmacists—as opposed to lay health workers or peers (RU = 21.5, 5.9, -24.5;  $p < 0.05$ ); and preferred an individual support system over a group support system (RU = 15.0 and 4.2;  $p < 0.05$ ). Likewise, patients strongly preferred longer intervals between both clinical

SQL programming language. The data was stored this way by the software that we used for our study.

**Funding:** EG received a grant from the National Institutes of Health under the terms of K24 AI134413 (<https://www.nih.gov>). SD received a travel grant from the University of California-San Francisco to cover international transportation and housing costs for the primary author. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

reviews (RU = 40.1 and -50.7 for 6- and 1-month spacing, respectively;  $p < 0.05$ ) and between ART collections (RU = 33.6 and -49.5 for 6- and 1-month spacing, respectively;  $p < 0.05$ ).

## Conclusion

Although health systems find community- and peer-based DSD models attractive, clinically stable patients expressed a preference for facility-based care as long as clinical visits were extended to biannual. These data suggest that multi-month scripting and fast-track models best align with patient preferences, an insight which can help prioritize use of different DSD models in the region.

## Introduction

Despite greatly expanded access to antiretroviral therapy (ART), about 30% of people living with HIV (PLHIV) in Kenya have not achieved consistently suppressed HIV viral load [1–4]. Treatment for HIV in the country over the last decade has been conducted using a “one-size-fits-all model” that was developed during the emergency response phase of the initial HIV epidemic and which focused on treating patients with advanced medical disease [5]. Patients—regardless of their age, socioeconomic status, CD4 levels, and medical stability—are required to visit the clinic every 1–3 months and to collect their medication just as often [5].

DSD models, which vary the timing, frequency, location and cadre of delivering care, have recently arisen as an alternative to the traditional model and have been heralded as a strategic solution to enhance the effectiveness and efficiency of the care cascade [6–9]. Many patients who are clinically stable need not expend considerable opportunity costs to visit facilities monthly or even quarterly to receive high quality care. Reduction of unnecessary visits would also ameliorate overburdened clinic facilities, reduce waiting time, and potentially improve health care worker burnout. DSD models like multi-month scripting, fast track, adherence clubs, and community ART groups all attempt to reduce visits, offset labor from health care workers to peers and patients, and encourage community-based treatment [5].

As DSD models continue to expand and require maintenance, public health implementers may need to select between models, as implementing multiple models may be burdensome. One way to assign prioritization could be to identify which features are most desired by patients, information which is to date relatively poorly understood. There are many variations of innovations in DSD, and identifying features that are preferred can suggest which are most likely to lead to sustained engagement and retention. For example, DSD includes strategies to deliver HIV care outside of the health facility and deliver care with peers or non-clinicians. Do patients prefer community-based care over facility-based care, and by how much? If they come to the facility rarely, do they prefer higher-cadre health workers, and by how much? DSD models are a large and diverse set of practices, and the comparative desirability of each model may influence which to prioritize. While some data exist on comparative effectiveness of different models, these experimental trials have not accounted for patient preferences which could be an important driver of success for a given individual [10, 11].

We propose to advance our understanding of patient preferences for innovations in HIV care through use of a discrete choice experiment. This discrete choice experiment (DCE) asked patients to choose between hypothetical models of care, which differ in certain attributes such as social support, frequency of clinical visits, and location of visits. In doing so, DCEs

offer an efficient way to examine the potential effectiveness of DSD by quantifying preferences in a population [12, 13]. Services that are most preferred by patients are most likely to be taken up and are most likely to yield consistent engagement. We aimed to reveal which attributes of treatment programs would be most important to patients, which can yield information relevant to policy makers.

## Materials and methods

This study took place in a dedicated HIV clinic in Kisumu County in Western Kenya between April 25, 2017 and June 6, 2017. This HIV clinic is a public health facility operated by the Kisumu County Health Department and supported by Family AIDS Care and Education Services (FACES), a collaboration between the University of California, San Francisco and the Kenya Medical Research Institute [14]. Stable HIV patients were recruited from the facility based on the following criteria: Age greater than or equal to 20 years, BMI greater than 18.5, most recent viral load less than 5,000 copies/mL, on current ART regimen for greater than 12 months, adherent to scheduled clinic visits for the past 6 months, non-pregnant/not breast-feeding, and the primary healthcare team does not have concerns about providing longer follow-up intervals for the patient. These criteria mirror those utilized by the Kenyan Ministry of Health as patients potentially eligible for DSD models [15]. Additionally, the Kenyan Ministry of Health has recently encouraged all patients living with HIV to undergo 6 months of isoniazid prevention therapy; however, this has not been fully implemented at the current HIV clinic and was not included in our inclusion criteria.

Attributes for the discrete choice experiment were identified primarily through a literature search on differentiated care in the region [16–19]. Although not all of these studies were conducted in Kenya, the attributes identified were applicable to HIV care in the country. We confirmed the validity of these attributes by conducting qualitative interviews with the FACES differentiated care team, clinicians at the HIV clinic, and other healthcare personnel who worked with the HIV+ population. Of the original seven attributes that were identified, all seven were ultimately included in our final design. We categorized the levels of each attribute with a similar process. All attributes and their levels are listed below (Table 1).

Questionnaires were produced by using the Choice-based Conjoint feature of Sawtooth Software™, which is widely used for DCE design, administration, and analysis [20]. Choice tasks were generated that maximize balance—meaning each level appears with the same frequency—and orthogonality—meaning each pair of levels appears with the same frequency across each pair of attributes. The experimental design generated 10 choice tasks that were

**Table 1. Attributes and levels of differentiated care models for HIV in Kenya.**

Attributes	Levels			
Location of ART refills	Health facility <sup>1</sup>	Community meeting point	Home	
Frequency of receiving ART refills	Every month	Every 3 months	Every 6 months	
Person providing ART refills	Nurse	Lay health worker	Pharmacist	PLHIV <sup>2</sup>
Adherence (adh) support provided <sup>3</sup>	No adh support	Individual adh support	Group adh support	
Refill pick-up/delivery times	Weekday during facility hours	Weekday (early morning, evening)	Weekend	
Location of viral load sample	Health facility <sup>1</sup>	Community meeting point	Home	
Frequency of clinical visits	Every month	Every 3 months	Every 6 months	Every 12 months

<sup>1</sup>Either HIV-specific or integrated primary care clinic

<sup>2</sup>Either participant or other member of the group, community peer

<sup>3</sup>Individual or group counseling around ART adherence, either by peers or health workers

<https://doi.org/10.1371/journal.pone.0255650.t001>

Table 2. Example of choice task.

**If these differentiated care models (DCMs) were your only options, which one would you choose? Please put an X under that DCM.**

Attributes	DCM 1	DCM 2	DCM 3
Location of ART refills	Community meeting point	Home	Health Center
Frequency of receiving ART refills	every 3 months	Every 3 months	Every month
Adherence support provided	No support	Individual support	Group support
Person providing ART refills	Pharmacist	PLHIV	Nurse
		X	

<https://doi.org/10.1371/journal.pone.0255650.t002>

added to the questionnaire, with each choice task asking a patient to choose between three hypothetical care models that have different levels of attributes (Table 2). A forced-choice format (i.e. no option to opt out of all three care models altogether) was used in order to more closely approximate the choice that a patient would have to make in real life, assuming that a stable patient with HIV would necessarily choose any care model over none at all.

Sawtooth generates the design by sampling from a subset of the full-choice designs for each respondent while ensuring level balance and near-orthogonality within each respondent's profile. This allows for the generation of up to 999 blocks, and using a unique randomized design for each respondent reduces context effects. We used a fractional factorial design to reduce the number of choice tasks required in the experiment and removed combinations of attributes and levels that would not be feasible or practical (e.g. patient receiving ART refill at clinic but having viral load taken at home). Finally, we used a partial profile design wherein each choice task was limited to four attributes rather than the total seven. Compared to full profile, a partial profile design reduces the cognitive burden on patients and thus lowers response error, producing results with greater predictive validity [21].

Patients were randomly allocated to receive one of twelve different, randomly-generated versions of the questionnaire, which had been translated to Dholuo and Kiswahili and uploaded onto Sawtooth servers. These questionnaires were accessed via Android tablets at the HIV clinic. Patients were given verbal instructions at the start of the interview and before each choice task to ensure understanding of the care models being presented. Each attribute and level was explained, and patients were allowed to complete the survey at their own pace.

To have enough power to reveal main effects, we needed a minimum of 67 patients based on the following sample size calculation for conjoint-based analysis in discrete choice experiments:

$$\frac{nta}{c} \geq 500$$

where  $n$  is the number of patients,  $t$  is the number of choice tasks per questionnaire ( $t = 10$  in our study),  $a$  is the number of options per choice task ( $a = 3$ ), and  $c$  is the number of cells ( $c = 4$ ) [22, 23]. To have enough power to examine all two-way interactions between attributes, we needed 267 patients based on the same formula as above, setting  $c = 16$  to reflect the largest product of levels of any two attributes.

Patients were introduced to the study during their clinician visit if they met criteria as a stable patient. One of three researchers approached each interested patient to obtain oral consent, and administered the questionnaire containing sociodemographic information and the ten choice tasks in the language of the patient's choosing. Patient IDs were also collected to obtain additional data from the EMR. Detailed field notes and observations were taken in tandem. Basic demographic information was collected from all participants: age, gender, education level, average monthly income, and average travel time to the clinic.

We used parametric and non-parametric tests to summarize all sociodemographic information using R version 3.2.3 [24]. Significance testing for continuous variables was completed using Student's t-test or Wilcoxon's Rank Sum test where appropriate and for categorical variables using Chi Square or Fisher's exact test where appropriate. Relative utilities and average importance for each of the levels and attributes, respectively, were calculated by Sawtooth Software using Hierarchical Bayesian (HB) analysis and effects coding [22, 24]. Compared to mixed logit or latent class models which may be used to analyze DCE data, HB analysis uses a two-level hierarchical model to generate both relative utilities for the population as well as individual utilities which can be used to identify detailed preference segments in the population. The HB model in Sawtooth has two levels: At the upper level, it is assumed that individuals' vectors of part-worths are drawn from a multivariate normal distribution [25]. At the lower level, a logit model is assumed for each individual, where the utility of each alternative is the sum of the part-worths of its attribute levels, and the respondent's probability of choosing each alternative is equal to its utility divided by the sum of utilities for the alternatives in that choice set [25]. Several Markov Chain Monte Carlo (MCMC) simulations of an algorithm using these model estimates generates the part-worths for the individuals, the mean for the population, and variances and covariances [25]. Represented as a formula, the utility function we used is described by Rao et al as follows:

$$U_i(x_{jt}) = D_{t1}U_{t1} + D_{t2}U_{t2} + \dots + D_{tr_t}U_{tr_t}$$

$$U_{t(x_{jt})} \sim N(Dt_i U_{t_i})$$

Where  $U_t$  = part-worth function of the  $t^{\text{th}}$  attribute;  $x_{jt}$  = level for the  $j^{\text{th}}$  profile on the  $t^{\text{th}}$  attribute;  $r_t$  = number of levels for the  $t^{\text{th}}$  attribute;  $D_{tk} = 1$  if the value  $x_{jt}$  is equivalent to the  $k^{\text{th}}$  discrete level of  $x_t$  and 0 otherwise; and  $U_{tk}$  = component of the part-worth function for the  $k^{\text{th}}$  discrete level of  $x_t$  [26]. The effect of each attribute of our DCE was modeled by:

$$U_t(x_{jt}) = D_i \left( \frac{t_1 + t_2 + \dots + t_n}{k} \right) * U_i$$

Where  $D_i$  = the discrete value assigned for each of  $i^{\text{th}}$  attributes;  $k$  = the discrete level of  $x_i$ ; and  $t_1+t_2+\dots+t_n$  is the sum of the attributes at the  $n^{\text{th}}$  level.

In addition, average importances are calculated in Sawtooth via standard probability analysis by dividing the utility range for each attribute (i.e. the utility of the highest level minus the utility of the lowest level) by the total sum of utility ranges for all attributes [22]. Average importances are reported as percentages and can be interpreted as how important each attribute is for a patient when making a decision regarding their preferred DSD model [20]. Descriptive statistics were used to describe any differences in relative utilities or importances across various socio demographic groups, although the study was not powered to confidently detect differences between sub-groups. Qualitative data from field notes were summarized using narrative analysis, whereby researchers identified common unifying stories that arose in response to probing questions about patients' decision-making process [27].

This evaluation was approved by the Kenya Medical Research Institute Ethical Review Committee and the University of California San Francisco Human Research Protection Program as part of routine program evaluation within the Family AIDS Care and Education Services (FACES) program.

## Results

### Sociodemographic characteristics

A total of 104 stable patients with HIV were recruited from the HIV clinic in Kisumu over a 5-week period beginning May 2017. The mean age of our study sample was 41 years, and 62.5% of the participants were women (Table 3). Women were significantly younger with a lower income than their male counterparts (Table 4).

### Relative utilities and importances

Relative utilities (RUs) represent patient preference and were calculated for each level of the discrete choice experiment (Table 5).

For location of ART refills, patients strongly preferred a model of care where they received ART at the health center, followed by a home-delivery model, followed by a community-point-delivery model (RU = 49.95, -3.88, and -46.07). The same trends were found for location of clinical review (RU = 69.28, -16.19, and -53.10).

**Table 3. Sociodemographic characteristics of HIV-infected patients (n = 104).**

Characteristic	Number (%)	Mean	Std Dev
<u>Gender</u>			
Men	39 (37.5)		
Women	65 (62.5)		
Other	0 (0.0)		
<u>Age (yrs)</u>			
18–34.9	32 (30.8)	41.06	10.89
35–49.9	47 (45.2)		
50–64.9	23 (22.1)		
> = 65	2 (1.9)		
<u>Survey Language</u>			
English	51 (49.0)		
Kiswahili	12 (11.5)		
Dholuo	41 (39.4)		
<u>Education Level<sup>1</sup></u>			
None	1 (1.0)		
Primary	50 (48.1)		
Secondary	41 (39.4)		
Univ/Postgrad	12 (11.5)		
<u>Income (KSH/mo)</u>			
Below PL <sup>2</sup>	61 (58.7)	9161	12966
Low income <sup>3</sup>	36 (34.6)		
Middle income+	7 (6.7)		
<u>Travel time (min)</u>			
0–29.9	26 (25.0)	48.08	44.9
30–59.9	47 (45.2)		
> = 60	31 (29.8)		

<sup>1</sup>Indicates highest level of education started or completed

<sup>2</sup>PL = Poverty line, monthly income below KSH 6200

<sup>3</sup>Low income = Monthly income between KSH 6200 and 26000

<https://doi.org/10.1371/journal.pone.0255650.t003>

**Table 4. Comparison of continuous and categorical variables by gender amongst HIV-infected patients (n = 104).**

Continuous Variable	Gender		test stat	p
	Men	Women		
Age, mean (yrs)	44.64	38.91	t = 2.553	*0.013
Income, median (KSH/mo)	7000	4000	W = 1590	*0.03
Travel time, median (min)	30	30	W = 1373	0.466
Categorical Variable	Men	Women	test stat	p
<u>Survey Language</u>			$\chi^2 = 5.92$	0.052
English, n	22	29		
Kiswahili, n	7	5		
Dholuo, n	10	31		
<u>Education Level</u>			Fisher	0.858
None, n	0	1		
Primary, n	17	33		
Secondary, n	17	24		
Univ/Postgrad, n	5	7		

\* significant at p < 0.05.

\*\* significant at p < 0.01.

Histogram of all significant differences provided on the right.

<https://doi.org/10.1371/journal.pone.0255650.t004>

For frequency of ART refills, patients preferred a model of care where they only had to collect their drugs every 6 months, followed closely by a model with ART refills every 3 months (RU = 33.63 and 15.89). They overwhelmingly did not prefer a 1-month ART refill system

**Table 5. Average utilities of all levels included in our study.**

Attributes and Levels	Avg Utilities	95% CI	Std Dev	95% CI	Attributes and Levels	Avg Utilities	95% CI	Std Dev	95% CI
<u>Location of ART Refills</u>					<u>Adherence Support</u>				
Health Centre	50.0	(37.45, 62.45)	64.26	(,)	No support	-19.3	(-23.77, -14.76)	23.15	(,)
Community meeting point	-46.1	(-56.00, -36.14)	51.05	(,)	Individual support	15.0	(10.71, 19.35)	22.19	(,)
Home	-3.9	(-14.41, 6.65)	54.15	(,)	Group support	4.2	(-0.61, 9.08)	24.92	(,)
<u>Location of Clinical Review</u>					<u>Person delivering ART</u>				
Health Centre	69.3	(57.95, 80.62)	58.30	(,)	Nurse	-2.8	(-6.88, 1.22)	20.81	(,)
Community meeting point	-53.1	(-61.83, -44.36)	44.93	(,)	Pharmacist	21.4	(17.09, 25.80)	22.39	(,)
Home	-16.2	(-27.80, -4.58)	59.71	(,)	PLHIV (community peer)	-24.5	(-29.04, -19.94)	23.40	(,)
<u>Frequency of ART Refills</u>					<u>Lay health worker</u>				
Every month	-49.5	(-56.38, -42.67)	35.24	(,)	Lay health worker	5.9	(1.35, 10.40)	23.27	(,)
Every 3 months	15.9	(12.08, 19.71)	19.60	(,)	<u>Refill delivery time</u>				
Every 6 months	33.6	(27.80, 39.46)	29.96	(,)	Weekday (regular hours)	16.3	(11.61, 21.02)	24.18	(,)
<u>Frequency of Clinical Rev</u>					Weekend				
Every month	-50.7	(-56.85, -44.56)	31.58	(,)	Weekend	-14.5	(-18.58, -10.44)	20.93	(,)
Every 3 months	7.4	(3.80, 10.96)	18.42	(,)					
Every 6 months	40.1	(33.52, 46.72)	33.95	(,)					
Every 12 months	3.2	(-2.02, 8.44)	26.90	(,)					

A higher magnitude (or darker shade) indicates a stronger preference, while a positive or negative value (green or red) indicates a positive or negative preference.

\*Red represents the least preferred attribute level and green represents the most preferred.

\*All differences are statistically significant at p < 0.05, except for 3 months vs 12 months for Frequency of Clinical Review

<https://doi.org/10.1371/journal.pone.0255650.t005>

relative to the other two options (RU = -49.53). Similarly, for frequency of clinical review, patients strongly preferred a model of care where they had a 6-month time between clinical appointments (TCA), followed by either a 3-month or 12-month TCA, and a strong preference against a 1-month TCA (RU = 40.12, 7.38, 3.21, and -50.71).

For adherence support provided, patients preferred an individual support system (i.e. one-on-one counseling) over a group support system. However, they preferred either option over having no support at all (RU = 15.03, 4.23, and -19.27). Patients preferred that the person delivering ART be a pharmacist, followed by a lay health worker, followed by a nurse, and finally by a community peer/PLHIV (RU = 21.45, 5.87, -2.83, and -24.49). Finally, for refill pick-up/delivery times, patients preferred to collect their drugs during regular clinic hours—between 8 AM and 4 PM—instead of off-hours or on the weekend (RU = 16.31, -1.80, and -14.51).

The average importance of each attribute of a care model is presented in Table 6. The location of clinical review and the location of ART refills were the most important attributes in the decision-making process when patients were faced with the choice tasks, and both were significantly more important to patients than any other attributes ( $p < 0.05$ ).

The next most important attributes were the frequency of clinical review and the frequency of ART refill, with average importances of 15.18 and 13.50, respectively. These are followed in importance by the person providing ART, the form of adherence support provided, and the schedule for ART refill delivery (Avg. Importance = 9.65, 8.19, and 7.78, respectively).

### Differences in DCE results by gender

Differences in relative utilities between men and women were also assessed (Table 7). Both men and women strongly preferred to receive their ART at a health center than at a community meeting point or at home, but women found home-based delivery more acceptable than did men (RU = 9.76 and -24.47, respectively;  $p < 0.05$ ). Both genders also preferred to receive their drugs from a pharmacist rather than a nurse, lay health worker, or peer. Women, however, found it more acceptable to receive ART refills from lay health workers than did men (RU = 20.80 and -4.59;  $p < 0.05$ ).

Both men and women strongly disliked receiving their ART refills on a monthly basis, preferring instead to receive them at three, six, or twelve-month intervals. Men, however, had almost equal preference for three and six-monthly refills (RU = 28.1 and 36.0), whereas women highly preferred the latter (RU = 5.2 and 47.4;  $p < 0.05$ ). Both genders preferred six-monthly clinical review compared to one, three, or twelve-monthly options. Finally, men reported a stronger preference for a group-based support system than did women (RU = 25.01

**Table 6. Average importances of all attributes included in our study.**

Attribute	Avg Importances (%)	Std Dev	95% CI
Location of clinical review	24.1	6.6	(22.8, 25.4)
Location of ART Refills	21.6	7.6	(20.1, 23.1)
Frequency of clinical visits	15.2	6.0	(14.0, 16.3)
Frequency of ART refill	13.5	7.6	(12.0, 15.0)
Person providing ART	9.7	3.9	(8.9, 10.4)
Adherence Support	8.2	4.1	(7.4, 9.0)
Refill pick-up/deliv time	7.8	3.9	(7.0, 8.5)

The values represent what proportion of a patient's decision was made based on that attribute. A higher value indicates that the attribute is considered more important by patients when choosing a model of care.

<https://doi.org/10.1371/journal.pone.0255650.t006>



Table 7. Normalized average utilities of all levels by gender.

Attributes and Levels	Gender							
	Men				Women			
	Avg Utilities	95% CI	Std Dev	95% CI	Avg Utilities	95% CI	Std Dev	95% CI
<u>Location of ART Refills</u>								
Health Centre	62.2	(39.47, 84.99)	70.2	(61.79, 81.31)	45.1	(26.68, 63.56)	74.4	(65.49, 86.17)
Community meeting point	-37.8	(-54.28, -21.26)	50.9	(44.82, 58.97)	-54.9	(-69.68, -40.08)	59.7	(52.57, 69.17)
Home*	-24.5	(-38.24, -10.70)	42.5	(37.38, 49.19)	9.8	(-5.38, 24.90)	61.1	(53.78, 70.77)
<u>Location of Clinical Review</u>								
Health Centre	57.0	(37.69, 76.31)	59.6	(52.43, 68.99)	57.0	(41.09, 73.01)	58.3	(51.31, 67.51)
Community meeting point	-43.0	(-54.27, -31.73)	34.8	(30.60, 40.26)	-43.0	(-57.62, -28.29)	59.3	(52.19, 68.67)
Home	-14.0	(-29.89, 1.88)	49.0	(43.12, 56.74)	-14.1	(-33.07, 4.87)	60.3	(53.07, 69.82)
<u>Frequency of ART Refills</u>								
Every month	-64.0	(-76.34, -51.76)	37.9	(33.36, 43.90)	-52.6	(-62.29, -42.94)	39.1	(34.37, 45.23)
Every 3 months*	28.1	(21.39, 34.80)	20.7	(18.20, 23.95)	5.2	(-1.46, 11.92)	27.0	(23.76, 31.26)
Every 6 months	36.0	(23.19, 48.71)	39.4	(34.65, 45.60)	47.4	(40.26, 54.50)	28.7	(25.29, 33.28)
<u>Frequency of Clinical Rev</u>								
Every month	-62.7	(-75.57, -49.80)	39.8	(34.99, 46.04)	-45.8	(-52.92, -38.67)	28.8	(25.30, 33.29)
Every 3 months	7.0	(0.21, 13.85)	21.0	(18.52, 24.36)	5.8	(-0.48, 12.01)	25.2	(22.19, 29.19)
Every 6 months	37.3	(26.18, 48.45)	34.4	(30.24, 39.79)	54.2	(46.12, 62.29)	32.6	(28.71, 37.78)
Every 12 months*	18.3	(10.05, 26.62)	25.6	(22.49, 29.60)	-14.2	(-21.12, -7.23)	28.0	(24.68, 32.47)
<u>Adherence Support</u>								
No support	-62.5	(-69.84, -55.16)	22.6	(19.93, 26.22)	-43.1	(-49.53, -36.72)	25.8	(22.74, 29.92)
Individual support	37.5	(26.44, 48.55)	34.1	(30.02, 39.50)	56.9	(52.27, 61.48)	18.6	(16.36, 21.52)
Group support*	25.0	(15.87, 34.15)	28.2	(24.81, 32.65)	-13.8	(-21.38, -6.13)	30.8	(27.08, 35.63)
<u>Person delivering ART</u>								
Nurse	3.1	(-7.18, 13.42)	31.8	(27.96, 36.79)	-10.9	(-15.40, -6.48)	18.0	(15.84, 20.85)
Pharmacist	50.7	(44.07, 57.40)	20.5	(18.08, 23.80)	45.1	(37.97, 52.18)	28.7	(25.23, 33.20)
PLHIV (community peer)	-49.3	(-59.91, -38.62)	32.9	(28.91, 38.04)	-54.9	(-64.27, -45.59)	37.7	(33.17, 43.64)
Lay health worker*	-4.6	(-18.16, 8.98)	41.9	(36.85, 48.49)	20.8	(15.14, 26.46)	22.9	(20.11, 26.47)
<u>Refill delivery time</u>								
Weekday (regular hours)	47.4	(36.57, 58.22)	33.4	(29.40, 38.68)	51.8	(46.20, 57.38)	22.5	(19.85, 26.11)
Weekday (off hours)	5.2	(-3.49, 13.90)	26.8	(23.61, 31.07)	-3.6	(-10.09, 2.93)	26.3	(23.12, 30.42)
Weekend	-52.6	(-60.91, -44.30)	25.6	(22.55, 29.67)	-48.2	(-53.76, -42.66)	22.4	(19.72, 25.94)

A higher magnitude indicates a stronger preference, while a positive or negative value indicates a positive or negative preference. A star (\*) denotes a level where preferences were significantly different between men and women ( $p < 0.05$ ).

<https://doi.org/10.1371/journal.pone.0255650.t007>

and -13.75;  $p < 0.05$ ). Though both genders still believed individual support was the best option, men viewed group support as a close second, whereas women did not.

### Field notes and observations

Field notes were taken during each interview by the researcher conducting the questionnaire. If patients cited a specific reason for their decision in a choice experiment, this was documented in notes that were reviewed at the end of the study period.

A majority of patients interviewed preferred models of care in which ART delivery and clinical review were both performed at the health center, as opposed to a community-meeting point or at home. Stigma against HIV was most commonly cited as the reason for this preference.

Patients almost unanimously preferred models of care with longer periods of time between either clinical reviews or ART deliveries. Work and travel restrictions were cited as the most common reasons for this preference

Most patients strongly preferred to receive their drugs from the pharmacist because they view pharmacists as those with the most training for the task. However, a few patients had interacted with lay health workers before, and were fine with models of care that utilize these individuals to take charge of ART delivery.

Patients unanimously preferred some form of social support over none at all. However, given the choice between an individual support or a group support system, patients chose the former. Patients reported fear of stigma, lack of individualized attention to understand how to adhere to one's medications, and challenges in managing a group dynamic as reasons they did not want a group support system.

Finally, most patients preferred care models in which ART delivery and clinical review happened during regular clinic hours simply because this is what they were used to. However, a few patients saw value in off-hours care, particularly if it allowed them more flexibility in their work.

## Discussion

Our discrete choice experiment revealed clear preferences of certain features of HIV care and treatment among PLHIV in Kenya with immediate implications for public health programming. Patients desired to come to the facility less frequently, with six-month intervals showing the greatest utilities. Patients, however, also valued location of care highly when choosing between models: counter to expectations, they strongly preferred models where clinical review and ART refills were done at a central location (e.g. the health clinic) instead of at home or in the community. Patients strongly preferred to interact with healthcare professionals: they preferred physicians/pharmacists rather than peers, and they preferred individual psychosocial support rather than group therapy.

Our findings support previous literature that suggests that excessive visits to the facility for clinical review or medication refill represents an undesired barrier. At present, standard of care in Kenya has increased visit intervals from monthly to quarterly [14], but these data suggest even longer intervals would be more preferred. Six months appeared to be the optimal period, as patients felt a decreasing utility associated with yearly visits for clinical review [28]. These data also mirror observation studies that suggest that a visit interval of six months was associated with a smaller chance of a missed visit as compared to shorter assigned return intervals. While at present the Kenya Ministry of Health recommends 3 months as an upper limit for ART to accommodate supply chain and stocking [28, 29], these data suggest a potential public health benefit to developing the capability to procure, maintain, and distribute enough ART to dispense 6-months of medications.

Many studies have shown the efficacy of community-based forms of HIV care in Kenya and SSA at large in reducing the burden on the facility, alleviating clinician workload, and reducing frequency of clinical appointments (TCA) [30–32]. Although community-based care seems beneficial from a systems standpoint, we found that patients themselves strongly prefer facility-based care models, and patients would often choose a facility-based care model even if it meant sacrificing other benefits such as reduced travel time, individual counseling, or less frequent TCA. Additionally, other studies have proposed using peer health workers and other lay health providers to help decrease health facility staff workloads. However, our study indicates that the person responsible for delivering care was also an important attribute for patients. Patients strongly preferred to receive care by facility-based workers (i.e. clinicians

and pharmacists), and not from PLHIV. One predominant barrier to the implementation of community- or peer-based models of care is the continued high level of stigma and discrimination against patients with HIV in Kenya, which was noted multiple times from field notes during the study [33–35].

Participants in our study prefer to have some form of psychosocial support to help them manage their condition. We observe that many clinics in the region have already led the way in the design and implementation of group support systems for PLHIV, albeit with varying levels of success [36]. However, given the option between an individual support system—such as one-on-one counseling—and a group support system, patients showed a preference towards the former.

Kenya's ongoing push for universal healthcare must be considered when examining our study results. Barriers to this goal include the gap in healthcare access between rural and urban communities, redundancies in service delivery, and a relative shortage of healthcare workers [37, 38]. In addition to being the model most preferred by the patients in our study, a multi-month scripting, fast-track model of care would also help improve the efficiency of the healthcare system and reduce the amount of time spent by workers on stable patients. As HIV/AIDS remains amongst the leading causes of death and disability in the country, adaptation of this model would aid in Kenya's efforts to refinance and restructure the healthcare system to provide universal coverage [37, 38].

Our study's primary strength lies in its design. DCEs provide more useful information than does traditional qualitative research in several ways. First, our study allowed us to not only rank, but also to quantify the magnitude of patient preferences for each attribute and corresponding levels. Such information will be useful for implementors who need to prioritize between several service characteristics when designing a DSD model. Second, our questionnaires simulated choices that patients may have to make in real life, which provides more earnest insight into a patient's preferences than would a traditional survey. Finally, we used prohibitions to ensure that all randomly generated care models would be feasible, so that patients would not be choosing between options that could never exist. Some of our findings support previous research, but many also challenge conventional approaches to differentiated care in Kenya.

However, our study had a few limitations. First, we did not meet the sample size goal to examine all two-way interactions between attributes. Our sample was large enough to reveal all significant within-attribute differences, but not large enough to analyze how preferences might vary between certain sociodemographic characteristics like income or level of education. Future research should prioritize understanding how preferences vary amongst different groups of patients. In addition, it will be important to explore how a patient's preference for one aspect of a care model might influence their preference for another (e.g. how does the preference for location of ART delivery interact with preference for type of support system). Second, we recruited from a naïve population of stable patients in Kisumu. None of the patients interviewed had any previous exposure to any form of differentiated care, so all of their responses were based on what they deemed to be the hypothetical best option. However, this may account for some of the differences seen in which differentiated care choices were acceptable in this study versus other studies where patients were assessed for their thoughts on a model after participating in it. For example, one year after implementation of a community ART group in Lesotho, patients reported overall satisfaction with the care model, citing reduced stigma against HIV in their community in addition to the expected benefits of reduced visit time and increased retention [39].

Finally, the COVID-19 pandemic may reshape patient preferences and health systems practices in a way that we cannot predict with our current data. Certain changes to HIV care in

Kenya in response to COVID-19 coincide with findings from our study. For example, the Kenyan Ministry of Health was recently able to procure and distribute an additional 3-month supply of ART to all FACES HIV clinics in Kenya, effectively increasing the space between ART refills leading to a 50.7% reduction in average daily clinic attendance [40]. This practice coincides with our finding that patients strongly prefer longer spacing between ART refills. However, other changes may be inconsistent with findings from our study. For example, FACES and the Kenyan Ministry of Health have created a goal to scale-up community distribution of ART in order to further decongest clinics and thus reduce transmission of COVID-19 [36]. It is conceivable that patient preference may shift to community- and home-delivery of ART in light of COVID-19. While we cannot assess this and other potential changes with our current data, we believe that this DCE will be useful to ensure that health systems provide the right mix of choices to meet changing patient preferences.

## Conclusions

Differentiated care promises to reduce system inefficiencies—such as unnecessary resources used on stable patients—while simultaneously improving patients' experiences with and retention in treatment regimens. As new research emerges and clinics throughout the country begin to test early forms of differentiated care, special attention must be paid to consider patient preferences in the design and implementation of these care models. Most importantly, we found that patients strongly prefer to stay in a centralized model of HIV care—one in which care is delivered in a health facility by trained health workers. This data must be taken into account in conjunction with the realities of limitations in care provision, but we must remain diligent in finding ways to improve HIV care in Kenya without sacrificing the needs and desires of patients themselves.

## Supporting information

**S1 Dataset. Raw data generated by Sawtooth Software based on the questionnaires submitted by the patients in our study.** This data can only be accessed by software that uses SQL programming language, such as Sawtooth.  
(XLSX)

## Acknowledgments

Thank you to the directors of the Global Health program at the University of California-San Francisco who supported this research academically. Finally, a special thanks to the clinicians and staff at Lumumba health clinic in Kisumu, Kenya where this research was conducted.

## Author Contributions

**Conceptualization:** Sagar Dommaraju, Thomas A. Odeny, Elvin Geng.

**Data curation:** Sagar Dommaraju, Sharon Okaka, Elvin Geng.

**Formal analysis:** Sagar Dommaraju, Elvin Geng.

**Funding acquisition:** Sagar Dommaraju, Elvin Geng.

**Investigation:** Sagar Dommaraju, Thomas A. Odeny, Elvin Geng.

**Methodology:** Sagar Dommaraju, Jill Hagey, Thomas A. Odeny, Ingrid Eshun-Wilson, Elvin Geng.

**Project administration:** Sagar Dommaraju, Sharon Okaka, Elvin Geng.

**Resources:** Sagar Dommaraju, Thomas A. Odeny, Elvin Geng.

**Software:** Sagar Dommaraju, Elvin Geng.

**Supervision:** Sagar Dommaraju, Thomas A. Odeny, Craig R. Cohen, Elvin Geng.

**Validation:** Sagar Dommaraju, Thomas A. Odeny, Elvin Geng.

**Visualization:** Sagar Dommaraju, Elvin Geng.

**Writing – original draft:** Sagar Dommaraju, Jill Hagey, Thomas A. Odeny, Ingrid Eshun-Wilson, Elvin Geng.

**Writing – review & editing:** Sagar Dommaraju, Jill Hagey, Thomas A. Odeny, Sharon Okaka, Julie Kadima, Elizabeth A. Bukusi, Craig R. Cohen, Zachary Kwena, Ingrid Eshun-Wilson, Elvin Geng.

## References

1. National AIDS and STI Control Programme (NASCO), Preliminary KENPHIA 2018 report. Nairobi: NASCO; 2020.
2. Cherutich P, Kim AA, Kellogg TA, et al. Detectable HIV Viral Load in Kenya: Data from a Population-Based Survey. *PLoS One* 2016; 11: 1–14. <https://doi.org/10.1371/journal.pone.0154318> PMID: [27192052](https://pubmed.ncbi.nlm.nih.gov/27192052/)
3. Ministry of Health, National AIDS Control Council, Kenya. 2016. Kenya AIDS Response Progress Report 2016.
4. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2014. 90-90-90: An ambitious treatment target to help end the AIDS epidemic.
5. Broder M. Differentiated Care: A New Concept in the Worldwide Effort to End HIV. *MedPage Today*. 2016.
6. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. *WHO, Geneva* 2016; 2nd Edition: 237–68.
7. Maman D, Zeh C, Mukui I, et al. 2015. Cascade of HIV care and population viral suppression in a high-burden region of Kenya. *AIDS*, 29:1557–65. <https://doi.org/10.1097/QAD.0000000000000741> PMID: [26244395](https://pubmed.ncbi.nlm.nih.gov/26244395/)
8. Duncombe C, Rosenblum S, Hellmann N, et al. 2015. Reframing HIV care: putting people at the centre of antiretroviral delivery. *Trop Med Int Health*, 20(4):430–47. <https://doi.org/10.1111/tmi.12460> PMID: [25583302](https://pubmed.ncbi.nlm.nih.gov/25583302/)
9. World Health Organization (WHO). 2015. HIV Treatment and Care: What's New in Service Delivery.
10. Hanrahan CF, Schwartz SR, Mudavanhu M, et al. The impact of community- versus clinic-based adherence clubs on loss from care and viral suppression for antiretroviral therapy patients: Findings from a pragmatic randomized controlled trial in South Africa. 2019; *PLOS Medicine*: 1–15. <https://doi.org/10.1371/journal.pmed.1002808> PMID: [31112543](https://pubmed.ncbi.nlm.nih.gov/31112543/)
11. Geng EH, Holmes CB (2019) Research to improve differentiated HIV service delivery interventions: Learning to learn as we do. *PLOS Medicine* 16(5): e1002809 <https://doi.org/10.1371/journal.pmed.1002809> PMID: [31112546](https://pubmed.ncbi.nlm.nih.gov/31112546/)
12. Lindsay J Mangham, Kara Hanson, Barbara McPake; How to do (or not to do) . . . Designing a discrete choice experiment for application in a low-income country, *Health Policy and Planning*, Volume 24, Issue 2, 1 March 2009, Pages 151–158
13. Terris-Prestholt F., Neke N., Grund J.M. et al. Using discrete choice experiments to inform the design of complex interventions. *Trials* 20, 157 (2019) <https://doi.org/10.1186/s13063-019-3186-x> PMID: [30832718](https://pubmed.ncbi.nlm.nih.gov/30832718/)
14. Kulzer JL, Penner JA, Marima R, et al. 2012. Family model of HIV care and treatment: a retrospective study in Kenya. *J Int AIDS Soc*, 15:8. <https://doi.org/10.1186/1758-2652-15-8> PMID: [22353553](https://pubmed.ncbi.nlm.nih.gov/22353553/)
15. Ministry of Health, Kenya. 2016. Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya.

16. National AIDS and STI Control Programme (NASCOP), Kenya. 2016. Improving the Quality and Efficiency of Health Services in Kenya: A Practical Handbook for HIV Managers and Service Providers on Differentiated Care.
17. Geng E. 2014. Adaptive Strategies for Preventing and Treating Lapses of Retention in Care (AdaPT-R).
18. Larson E, Vail D, Mbaruku GM, et al. 2015. Moving toward patient-centered care in Africa: A discrete choice experiment of preference for delivery care among 3,003 Tanzanian women. *Plos One*, 10:1–12. <https://doi.org/10.1371/journal.pone.0135621> PMID: 26262840
19. Mangham LJ, Hanson K, Mcpake B. 2009. How to do (or not to do). . . Designing a discrete choice experiment for application in a low-income country. *Health Policy and Planning*, 24(2):151–8. <https://doi.org/10.1093/heapol/czn047> PMID: 19112071
20. Sawtooth Software. The CBC/HB System for Hierarchical Bayes Estimation. *Tech Pap Ser*, 1–30.
21. Chrzan K. Using partial profile choice experiments to handle large numbers of attributes. 2010; *International Journal of Market Research* 52(6).
22. Orme B. 2010. Getting Started with Conjoint Analysis: Strategies for Product Design and Pricing Research. Madison, WI: Research Publishers LLC.
23. Johnson FR, Lancsar E, Marshall D, et al. Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. 2013; 6: 3–13.
24. The R Foundation. 2017. The R Project for Statistical Computing.
25. Johnson RM. Understanding HB: An Intuitive Approach. Sawtooth Softw Res Pap Ser 2000.
26. Rao VR, Sheth JN, Malhotra NK. (2010). Conjoint Analysis. *Wiley International Encyclopedia of Marketing*.
27. Allen M. 2017, The sage encyclopedia of communication research methods, vol. 4, SAGE Publications, Inc, Thousand Oaks, CA
28. National AIDS and STI AIDS and STI Control Programme (NASCOP), Kenya. 2017. Differentiated Care: Operational Guide.
29. Larson C, Burn R, Minnick-Sakal A, et al. 2014. Strategies to reduce risks in ARV supply chains in the developing world. *Glob Health Sci Pract*, 2(4):395–402. <https://doi.org/10.9745/GHSP-D-14-00105> PMID: 25611474
30. Decroo T, Rasschaert F, Telfer B, et al. 2013. Community-based antiretroviral therapy programs can overcome barriers to retention of patients and decongest health services in sub-Saharan Africa: a systematic review. *Int Health*, 5(3):169–79. <https://doi.org/10.1093/inthealth/ih016> PMID: 24030268
31. Wouters E, Van Damme W, Van Rensburg D, et al. 2012. Impact of community-based support services on antiretorivral treatment program delivery and outcomes in resource-limited countries: a synthetic review. *BMC Health Serv Res*, 12(1):194.
32. Medecins Sans Frontieres (MSF): MSF Analysis & Advocacy Unit Brussels with Southern Africa Medical Unit. 2013. Reaching Closer to Home: Progress implementing community-based and other adherence strategies supporting people on HIV treatment.
33. Brown L, Macintyre K, Trujillo L. 2003. Interventions to reduce HIV stigma: What have we learned? *AIDS Educ Prev*, 15:49–69. <https://doi.org/10.1521/aeap.15.1.49.23844> PMID: 12627743
34. National Empowerment Network of People Living with HIV and AIDS in Kenya (NEPHAK). 2011. The People Living with HIV Stigma Index–Kenya.
35. Dlamini PS, Wantland D, Makoe LN, et al. 2009. HIV Stigma and Missed Medications in HIV-Positive People in Five African Countries. *AIDS Patient Care and STDs*, 23(5):377–87. <https://doi.org/10.1089/apc.2008.0164> PMID: 19327098
36. Khabala KB, Edwards JK, Baruani B, et al. 2015. Medication Adherence Clubs: A potential solution to managing large number of stable patients with multiple chronic diseases in informal settlements. *Trop Med Int Heal*, 20:1265–70.
37. Okech TC, Lelegwe SL. Analysis of Universal Health Coverage and Equity on Health Care in Kenya. *Glob J Health Sci* 2016; 8: 218–27.
38. Mbau R, Kabia E, Honda A, Hanson K, Barasa E. Examining purchasing reforms towards universal health coverage by the National Hospital Insurance Fund in Kenya. *Int J Equity Health*. 2020 Feb 3; 19(1):19. <https://doi.org/10.1186/s12939-019-1116-x> PMID: 32013955; PMCID: PMC6998279.
39. Vandendyck M, Motsamai M, Mubanga M, et al. Community-based ART resulted in excellent retention and can leverage community empowerment in rural Lesotho, a mixed method study. *HIV/AIDS Res Treat Open J*. 2015; 2(2): 44–50.
40. Odhiambo F, Mulwa E, Ayieko Jet al. 2020. Implementation of HIV care in Western Kenya during corona virus disease 2019 response. *AIDS* 2020, 33:000–000. <https://doi.org/10.1097/QAD.0000000000002576> PMID: 32501845